Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis

Archives of Clinical Neuropsychology

Volumn 28, Issue 2, 2013, Pages 144-155

  Sundgren, Mathias ^a   Maurex, Liselotte ^a   Wahlin, Åke ^b,c   Piehl, Fredrik ^a   Brismar, Tom ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Depression; Fatigue; Multiple sclerosis; Neuropsychological assessment; Physical disability; Psychotropic medication

Indexed keywords

EID: 84879179388     PISSN: 08876177     EISSN: 18735843     Source Type: Journal    
DOI: 10.1093/arclin/acs113     Document Type: Article

References (77)

1. Ahlgren, C., Oden, A., & Lycke, J. (2011). High nationwide prevalence of multiple sclerosis in Sweden. Multiple Sclerosis Journal, 17 (8), 901-908.
2. Aikens, J. E., Reinecke, M. A., Pliskin, N. H., Fischer, J. S., Wiebe, J. S., McCracken, L. M., et al. (1999). Assessing depressive symptoms in multiple sclerosis: Is it necessary to omit items from the original Beck Depression Inventory? Journal of Behavioral Medicine, 22 (2), 127-142.
3. Almkvist, O., Adveen, M., Henning, L., & Tallberg, I. M. (2007). Estimation of premorbid cognitive function based on word knowledge: The Swedish Lexical Decision Test (SLDT). Scandinavian Journal of Psychology, 48 (3), 271-279.
4. Amato, M. P., Zipoli, V., & Portaccio, E. (2006). Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies. Journal of the Neurological Sciences, 245 (1-2), 41-46.
5. Andreasen, A. K., Spliid, P. E., Andersen, H., & Jakobsen, J. (2010). Fatigue and processing speed are related in multiple sclerosis. European Journal of Neurology, 17 (2), 212-218.
6. Arai, S., Takuma, K., Mizoguchi, H., Ibi, D., Nagai, T., Kamei, H., et al. (2009). GABA(B) receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. European Journal of Pharmacology, 602 (1), 101-104.
7. Arnett, P. A., Barwick, F. H., & Beeney, J. E. (2008). Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society, 14 (5), 691-724.
8. Arnett, P., Ben-Zacharia, A., Benedict, R., Bobholz, J., Caruso, L., Chelune, G., et al. (2005). The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis, 11 (3), 328-337.
9. Arnett, P. A., Higginson, C. I., Voss, W. D., Wright, B., Bender, W. I., Wurst, J. M., et al. (1999). Depressed mood in multiple sclerosis: Relationship to capacity-demanding memory and attentional functioning. Neuropsychology, 13 (3), 434-446.
10. Arnett, P. A., & Strober, L. B. (2011). Cognitive and neurobehavioral features in multiple sclerosis. Expert Review of Neurotherapeutics, 11 (3), 411-424.
11. Bagert, B., Camplair, P., & Bourdette, D. (2002). Cognitive dysfunction in multiple sclerosis-Natural history, pathophysiology and management. CNS Drugs, 16 (7), 445-455.
12. Bakshi, R., Shaikh, Z. A., Miletich, R. S., Czarnecki, D., Dmochowski, J., Henschel, K., et al. (2000). Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Multiple Sclerosis, 6 (3), 181-185.
13. Barwick, F. H., & Arnett, P. A. (2011). Relationship between global cognitive decline and depressive symptoms in multiple sclerosis. Clinical Neuropsychologist, 25 (2), 193-209.
14. Beatty, W. W. (1998). Cognitive dysfunction in multiple sclerosis: Natural history and impact on productive living. Italian Journal of Neurological Sciences, 19 (6), S381-S387.
15. Beatty, W. W., Goodkin, D. E., Hertsgaard, D., & Monson, N. (1990). Clinical and demographic predictors of cognitive performance in multiple sclerosis-Do diagnostic type, disease duration, and disability matter. Archives of Neurology, 47 (3), 305-308.
16. Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck Depression Inventory-II. Manual. San Antonio, TX: The Psychological Corporation.
17. Beck, A. T., Steer, R. A., & Garbin, M. G. (1988). Psychometric properties of the Beck Depression Inventory-25 years of evaluation. Clinical Psychology Review, 8 (1), 77-100.
18. Benedict, R. H. B., Duquin, J. A., Jurgensen, S., Rudick, R. A., Feitcher, J., Munschauer, F. E., et al. (2008). Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Multiple Sclerosis, 14 (7), 940-946.
19. Benedict, R. H. B., Fishman, I., McClellan, M. M., Bakshi, R., & Weinstock-Guttman, B. (2003). Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Multiple Sclerosis Journal, 9 (4), 393-396.
20. Bergendal, G., Fredrikson, S., & Almkvist, O. (2007). Selective decline in information processing in subgroups of multiple sclerosis: An 8-year longitudinal study. European Neurology, 57 (4), 193-202.
21. Bol, Y., Duits, A. A., Hupperts, R. M. M., Vlaeyen, J. W. S., & Verhey, F. R. J. (2009). The psychology of fatigue in patients with multiple sclerosis: A review. Journal of Psychosomatic Research, 66 (1), 3-11.
22. Brismar, T., Maurex, L., Cooray, G., Juntti-Berggren, L., Lindstrom, P., Ekberg, K., et al. (2007). Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology, 32 (8-10), 1041-1051.
23. Chiaravalloti, N. D., & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. The Lancet Neurology, 7 (12), 1139-1151.
24. Chwastiak, L., Ehde, D. M., Gibbons, L. E., Sullivan, M., Bowen, J. D., & Kraft, G. H. (2002). Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample. American Journal of Psychiatry, 159 (11), 1862-1868.
25. Cook, S. D. (2001). Handbook of multiple sclerosis. New York: Marcel Dekker. Delis, D. C., Kaplan, E., & Kramer, J. H. (2001). Delis-Kaplan Executive Function System (D-KEFS). San Antonio, TX: The Psychological Corporation.
26. Demaree, H. A., Gaudino, E., & DeLuca, J. (2003). The relationship between depressive symptoms and cognitive dysfunction in multiple sclerosis. Cognitive Neuropsychiatry, 8 (3), 161-171.
27. Dureman, I., & Sälde, H. (1959). Psykometriska och experimentalpsykologiska metoder för klinisk tillämpning: Studies in psychometric and experimental methods for the clinical evaluation of mental functioning. Stockholm: Almqvist & Wiksell.
28. Feinstein, A. (2006). Mood disorders in multiple sclerosis and the effects on cognition. Journal of the Neurological Sciences, 245 (1-2), 63-66.
29. Gottberg, K., Einarsson, U., Fredrikson, S., von Koch, L., & Holmqvist, L. W. (2007). A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. Journal of Neurology Neurosurgery and Psychiatry, 78 (1), 60-65.
30. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6 (Dec), 278-296.
31. Harmer, C. J., Shelley, N. C., Cowen, P. J., & Goodwin, G. M. (2004). Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. American Journal of Psychiatry, 161 (7), 1256-1263.
32. Hindmarch, I. (2009). Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. International Journal of Clinical Practice, 63 (7), 1085-1094.
33. Holmen, C., Piehl, F., Hillert, J., Fogdell-Hahn, A., Lundkvist, M., Karlberg, E., et al. (2011). A Swedish national post-marketing surveillance study of nata-lizumab treatment in multiple sclerosis. Multiple Sclerosis, 17 (6), 708-719.
34. Huijbregts, S. C. J., Kalkers, N. F., de Sonneville, L. M. J., de Groot, V., & Polman, C. H. (2006). Cognitive impairment and decline in different MS subtypes. Journal of the Neurological Sciences, 245 (1-2), 187-194.
35. Johnson, S. K., DeLuca, J., & Natelson, B. H. (1996). Depression in fatiguing illness: Comparing patients with chronic fatigue syndrome, multiple sclerosis and depression. Journal of Affective Disorders, 39 (1), 21-30.
36. Julian, L., Merluzzi, N. M., & Mohr, D. C. (2007). The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis. Multiple Sclerosis, 13 (1), 81-86.
37. Khalil, M., Enzinger, C., Langkammer, C., Petrovic, K., Loitfelder, M., Tscherner, M., et al. (2011). Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Multiple Sclerosis, 17 (2), 173-180.
38. Kinsinger, S. W., Lattie, E., & Mohr, D. C. (2010). Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychologic-al functioning in patients with multiple sclerosis. Neuropsychology, 24 (5), 573-580.
39. Koch, M. W., Glazenborg, A., Uyttenboogaart, M., Mostert, J., & De Keyser, J. (2011). Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews, (2).
40. Krupp, L. B., Larocca, N. G., Muirnash, J., & Steinberg, A. D. (1989). The Fatigue Severity Scale-Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46 (10), 1121-1123.
41. Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis-An expanded disability status scale (EDSS). Neurology, 33 (11), 1444-1452.
42. Langdon, D. W. (2011). Cognition in multiple sclerosis. Current Opinion in Neurology, 24 (3), 244-249.
43. Lerdal, A., Celius, E. G., Krupp, L., & Dahl, A. A. (2007). A prospective study of patterns of fatigue in multiple sclerosis. European Journal of Neurology, 14 (12), 1338-1343.
44. Lynch, S. G., Parmenter, B. A., & Denney, D. R. (2005). The association between cognitive impairment and physical disability in multiple sclerosis. Multiple Sclerosis, 11 (4), 469-476.
45. Mattioli, F., Stampatori, C., & Capra, R. (2011). The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: Preliminary results of a 1-year follow-up study. Neurological Sciences, 32 (1), 83-88.
46. Middleton, L. S., Denney, D. R., Lynch, S. G., & Parmenter, B. (2006). The relationship between perceived and objective cognitive functioning in multiple sclerosis. Archives of Clinical Neuropsychology, 21 (5), 487-494.
47. Mohr, D. C., Goodkin, D. E., Likosky, W., Beutler, L., Gatto, N., & Langan, M. K. (1997). Identification of Beck Depression Inventory items related to multiple sclerosis. Journal of Behavioral Medicine, 20 (4), 407-414.
48. Mohr, D. C., Hart, S. L., Fonareva, I., & Tasch, E. S. (2006). Treatment of depression for patients with multiple sclerosis in neurology clinics. Multiple Sclerosis, 12 (2), 204-208.
49. Moller, F., Poettgen, J., Broemel, F., Neuhaus, A., Daumer, M., & Heesen, C. (2011). HAGIL (Hamburg Vigil Study): A randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Multiple Sclerosis Journal, 17 (8), 1002-1009.
50. Moran, P. J., & Mohr, D. C. (2005). The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. Journal of Behavioral Medicine, 28 (1), 35-41.
51. Morrow, S. A., Weinstock-Guttman, B., Munschauer, F. E., Hojnacki, D., & Benedict, R. H. B. (2009). Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Multiple Sclerosis, 15 (8), 998-1005.
52. O'Neill, W. M., Hanks, G. W., Simson, P., Fallon, M. T., Jenkins, E., & Wesnes, K. (2000). The cognitive and psychomotor effects of morphine in healthy subjects: A randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain, 85 (1-2), 209-215.
53. Oneill, W. M., Hanks, G. W., White, L., Simpson, P., & Wesnes, K. (1995). The cognitive and psychomotor effects of opioid analgesics. 1. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology, 48 (6), 447-453.
54. Patti, F., Amato, M. P., Trojano, M., Bastianello, S., Tola, M. R., Goretti, B., et al. (2009). Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: Baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis, 15 (7), 779-788.
55. Peretti, S., Judge, R., & Hindmarch, I. (2000). Safety and tolerability considerations: Tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, 101, 17-25.
56. Plumb, M. M., & Holland, J. (1977). Comparative studies of psychological function in patients with advanced cancer. 1. Self-reported depressive symptoms. Psychosomatic Medicine, 39 (4), 264-276.
57. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Annals of Neurology, 58 (6), 840-846.
58. Potagas, C., Giogkaraki, E., Koutsis, G., Mandellos, D., Tsirempolou, E., Sfagos, C., et al. (2008). Cognitive impairment in different MS subtypes and clinically isolated syndromes. Journal of the Neurological Sciences, 267 (1-2), 100-106.
59. Prakash, R. S., Snook, E. M., Lewis, J. M., Motl, R. W., & Kramer, A. F. (2008). Cognitive impairments in relapsing-remitting multiple sclerosis: A meta-analysis. Multiple Sclerosis, 14 (9), 1250-1261.
60. Psykologiförlaget (Ed.). (1971). Manual for the Dureman-Sälde tests. Stockholm: Psykologiförlaget AB.
61. Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology, 41 (5), 685-691.
62. Roxburgh, R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., et al. (2005). Multiple sclerosis severity score-Using disability and disease duration to rate disease severity. Neurology, 64 (7), 1144-1151.
63. Schmitt, J. A. J., Kruizinga, M. J., & Riedel, W. J. (2001). Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. Journal of Psychopharmacology, 15 (3), 173-179.
64. Schmidt, M. (1996). Rey Auditory and Verbal Learning Test. A handbook. Los Angeles: Western Psychological Services.
65. Shenal, B. V., Harrison, D. W., & Demaree, H. A. (2003). The neuropsychology of depression: A literature review and preliminary model. Neuropsychology Review, 13 (1), 33-42.
66. Siegert, R. J., & Abernethy, D. A. (2005). Depression in multiple sclerosis: A review. Journal of Neurology Neurosurgery and Psychiatry, 76 (4), 469-475.
67. Sivan, A. B. (1992). Benton Visual Retention Test-Fifth Edition. San Antonio, TX: The Psychological Corporation.
68. Strober, L. B., & Arnett, P. A. (2005). An examination of four models predicting fatigue in multiple sclerosis. Archives of Clinical Neuropsychology, 20 (5), 631-646.
69. Teasdale, T. W., Owen, D. R., & Sorensen, T. I. (1991). Intelligence and educational level in adult males at the extremes of stature. Human Biology, 63 (1), 19-30.
70. Teasdale, T. W., Sorensen, T. I., & Stunkard, A. J. (1992). Intelligence and educational level in relation to body mass index of adult males. Human Biology, 64 (1), 99-106.
71. Tellez, N., Rio, J., Tintore, M., Nos, C., Galan, I., & Montalbal, X. (2005). Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Multiple Sclerosis, 11 (2), 198-202.
72. Terzano, M. G., Rossi, M., Palomba, V., Smerieri, A., & Parrino, L. (2003). New drugs for insomnia-Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Safety, 26 (4), 261-282.
73. Tuvemo, T., Jonsson, B., & Persson, I. (1999). Intellectual and physical performance and morbidity in relation to height in a cohort of 18-year-old Swedish conscripts. Hormone Research, 52 (4), 186-191.
74. Wadsworth, E. J. K., Moss, S. C., Simpson, S. A., & Smith, A. P. (2005). SSRIs and cognitive performance in a working sample. Human Psychopharmacology-Clinical and Experimental, 20 (8), 561-572.
75. Wechsler, D. (1997). Wechsler Adult Intelligence Scale (3rd ed.). San Antonio, TX: The Psychological Corporation.
76. Zaccara, G., Gangemi, P. F., & Cincotta, M. (2008). Central nervous system adverse effects of new antiepileptic drugs-A meta-analysis of placebo-controlled studies. Seizure-European Journal of Epilepsy, 17 (5), 405-421.
77. Zobel, A. W., Schulze-Rauschenbach, S., von Widdern, O. C., Metten, M., Freymann, N., Grasmader, K., et al. (2004). Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment. Journal of Psychiatric Research, 38 (4), 377-383.